Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial
| Autor: | Mehdi Hamedi, Mona Shahriari, Atefeh Zeinoddini, Payam Mohammadinejad, Mohammad-Reza Kazemi, Zahra Keshavarzi, Rosa Alikhani, Shahin Akhondzadeh, Mohammad Reza Mohammadi, Ali Ghaleiha |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Placebo-controlled study Minocycline Irritability Placebo law.invention 03 medical and health sciences Lethargy 0302 clinical medicine Double-Blind Method Randomized controlled trial law Internal medicine medicine Humans Pharmacology (medical) Autistic Disorder Child Psychiatry Risperidone Repeated measures design Irritable Mood 030227 psychiatry Psychiatry and Mental health Treatment Outcome Child Preschool Pediatrics Perinatology and Child Health Adjunctive treatment Linear Models Drug Therapy Combination Female medicine.symptom Psychology 030217 neurology & neurosurgery Antipsychotic Agents medicine.drug |
| Zdroj: | Journal of Child and Adolescent Psychopharmacology. 26:784-791 |
| ISSN: | 1557-8992 1044-5463 |
| DOI: | 10.1089/cap.2015.0175 |
| Popis: | This is an investigation of minocycline efficacy and safety as an adjuvant to risperidone in management of children with autism.Forty-six children with diagnosis of autistic disorder, according to the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) criteria and a score of ≥12 on the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale, who were already drug-free for at least 6 months participated in a randomized controlled trial and underwent 10 weeks of treatment with either minocycline (50 mg twice per day) or placebo in addition to risperidone titrated up to 2 mg/day (based on bodyweight). Patients were evaluated using ABC-C at baseline and at weeks 5 and 10.General linear model repeated measures showed significant effect for time × treatment interaction on the irritability [F(2, 88) = 3.94, p = 0.02] and hyperactivity/noncompliance [F(1.50, 66.05) = 7.92, p = 0.002], but not for lethargy/social withdrawal [F(1.61, 71.02) = 0.98, p = 0.36], stereotypic behavior [F(1.34, 58.80) = 1.55, p = 0.22], and inappropriate speech subscale scores [F(1.52, 66.88) = 1.15, p = 0.31]. By week 10, 21 (91.3%) patients in the minocycline group and 15 (65.5%) patients in the placebo group achieved at least partial response (p = 0.03). Frequencies of adverse events were not significantly different between groups.Minocycline seems to be a safe and effective adjuvant in management of patients with autistic disorder. Future studies with larger sample sizes, longer follow-ups, and inflammatory cytokine measurements are warranted to confirm these findings and provide insight into minocycline mechanism of action in autistic disorder. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|